芪苈强心胶囊治疗心力衰竭的应用价值探究

Application value of Qili Qiangxin capsule in the treatment of heart failure

目的探究芪苈强心胶囊治疗心力衰竭的应用价值。方法64例心力衰竭患者,根据就诊先后顺序分为实验组与对照组,每组32例。两组均给予血管扩张剂、血管转换酶抑制剂和利尿剂、洋地黄制剂、β-受体阻滞剂药物等基础治疗,对照组患者给予心脏康复运动干预,实验组患者在对照基础上进行芪苈强心胶囊治疗。比较两组患者的治疗效果,心功能指标(左室射血分数、左室舒张末期内径、左室收缩末期内径、心输出量、心率、每搏输出量),N末端脑钠肽前体、6 min步行距离,不良反应发生情况。结果实验组患者的治疗总有效率为96.88%,高于对照组的81.25%,差异具有统计学意义(P<0.05)。实验组患者左室射血分数(46.23±4.79)%、心输出量(5.24±0.49)L/min、心率(69.21±11.26)次/min均高于对照组的(42.34±4.16)%、(4.76±0.41)L/min、(57.54±13.78)次/min,左室舒张末期内径(51.34±3.26)mm、左室收缩末期内径(42.54±3.76)mm、每搏输出量(69.21±11.26)ml均小于对照组的(55.14±4.11)mm、(46.75±4.06)mm、(77.23±9.49)ml,差异具有统计学意义(P<0.05)。实验组患者的N末端脑钠肽前体(382.16±201.64)ng/L低于对照组的(472.26±151.16)ng/L,6 min步行距离(322.87±4.72)m长于对照组的(290.53±3.26)m,差异具有统计学意义(P<0.05)。实验组患者的不良反应发生率12.50%明显低于对照组的34.38%,差异具有统计学意义(P<0.05)。结论心力衰竭患者采用芪苈强心胶囊治疗,有利于改善患者的心功能,避免出现不良反应,提高治疗效果,值得在临床推广。

Objective To investigate the application value of Qili Qiangxin capsule in the treatment of heart failure.Methods A total of 64 patients with heart failure were divided into experimental group and control group according to the order of consultation,with 32 patients in each group.Both groups were given basic treatment with vasodilators,angiotensin-converting enzyme inhibitor and diuretics,digitalis preparations,β-blocker drugs,etc.On this basis,patients in the control group received cardiac rehabilitation exercise intervention,and patients in the experimental group were treated with Qili Qiangxin capsule on the basis of control group.Both groups were compared in terms of therapeutic effects,cardiac function indexes(left ventricular ejection fraction,left ventricular end-diastolic diameter,left ventricular end-systolic diameter,cardiac output,heart rate,stroke volume),N-terminal pro-brain natriuretic peptide,6-min walking distance,and the occurrence of adverse reactions.Results The total effective rate of treatment for patients in the experimental group was 96.88%,which was higher than 81.25%in the control group,and the difference was statistically significant(P<0.05).The the experimental group had left ventricular ejection fraction of(46.23±4.79)%,cardiac output of(5.24±0.49)L/min,and heart rate of(69.21±11.26)beats/min,which were higher than(42.34±4.16)%,(4.76±0.41)L/min,and(57.54±13.78)beats/min in the control group;the experimental group had left ventricular end-diastolic diameter of(51.34±3.26)mm,left ventricular end-systolic diameter of(42.54±3.76)mm,and stroke volume of(69.21±11.26)ml,which were less than(55.14±4.11)mm,(46.75±4.06)mm,and(77.23±9.49)ml in the control group;the differences were statistically significant(P<0.05).The N-terminal pro-brain natriuretic peptide(382.16±201.64)ng/L in the experimental group was lower than(472.26±151.16)ng/L in the control group;the 6-min walking distance(322.87±4.72)m in the experimental group was longer than(290.53±3.26)m in the control group;the differences were statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was 12.50%,which was significantly lower than 34.38%in the control group,and the difference was statistically significant(P<0.05).Conclusion Qili Qiangxin capsule capsules for patients with heart failure can help improve the patient's heart function,avoid adverse reactions,and improve the therapeutic effect.It is worthy of clinical promotion.